8-K: DarioHealth Secures $18.8 Million in Private Placement, Extends Loan Maturity

DarioHealth Corp. has successfully raised approximately $18.8 million through a private placement of preferred stock and amended its loan agreement, extending its cash runway.

Summary

• DarioHealth Corp. has entered into securities purchase agreements with accredited investors, resulting in gross proceeds of approximately $18.805 million from the sale of Series D and Series D-1 Preferred Stock.
• The initial closing of the preferred stock occurred on December 18, 2024.
• Each share of preferred stock is convertible into common stock at an initial conversion price of $0.73, subject to adjustments.
• The preferred stock will automatically convert into common stock on the 12-month anniversary of the issuance date, with a 19.99% ownership blocker.
• Holders of the preferred stock are entitled to dividends equal to 10% of the common stock issuable upon conversion for each full quarter of holding, for a total of four quarters.
• The company also amended its loan agreement with Avenue Venture Opportunities Fund, extending the interest-only period and the loan maturity date to November 1, 2027, contingent on meeting certain milestones.
• The company will seek stockholder approval to reprice warrants issued to lenders to $0.7208 per share and allow lenders to convert up to $2 million of the loan at $0.8650 per share.
• The funds from the offering are expected to support the company in achieving a profitability run rate by the end of 2025.
• The company's proforma cash balance, including proceeds from the offering, is $34 million as of the end of the third quarter.
• These measures are expected to extend the company's cash runway until operational profitability is achieved under its current strategic plan.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and loan amendment. However, there are some risks and uncertainties, such as the need for stockholder approval and the achievement of financial milestones, which temper the overall sentiment.

Positives

• The private placement provides a significant capital infusion of $18.805 million.
• The extension of the loan maturity date to November 1, 2027, provides more financial flexibility.
• The company's proforma cash balance is $34 million, providing a solid financial base.
• The company is targeting profitability by the end of 2025.
• The refinancing and capital raise are expected to extend the company's cash runway until operational profitability is achieved.

Negatives

• The conversion of preferred stock is subject to stockholder approval, which introduces some uncertainty.
• The preferred stock has a non-waivable 19.99% ownership blocker, which may limit the potential upside for some investors.
• The conversion of the loan principal is subject to Nasdaq rules, which may introduce some uncertainty.

Risks

• The company's ability to achieve profitability by the end of 2025 is not guaranteed.
• The conversion of preferred stock is subject to stockholder approval, which may not be obtained.
• The company's ability to meet the revenue and cash burn milestones for the loan extension is not guaranteed.
• The company is subject to risks discussed in its filings with the SEC, which could cause actual results to differ from forward-looking statements.

Future Outlook

The company expects the funds from the offering and the loan amendment to support achieving a profitability run rate by the end of 2025 and extend the cash runway until operational profitability is achieved.

Management Comments

• The continued cost optimization efforts following the Companys acquisition of Twill Inc., along with consistent revenue growth across multiple channels, have positioned the Company on the path to profitability.
• The funds secured through the Offering are expected to support the Company in achieving a profitability run rate by the end of 2025.

Industry Context

This announcement reflects a trend of healthcare technology companies seeking capital to fund growth and achieve profitability. The private placement and loan amendment are strategic moves to strengthen DarioHealth's financial position and support its long-term goals.

Comparison to Industry Standards

• The private placement of preferred stock is a common method for growth-stage companies to raise capital, similar to other companies in the digital health space such as Livongo (prior to its acquisition) and Teladoc.
• The conversion price of $0.73 per share is within the range of similar financings for companies at this stage, but the specific terms of the preferred stock, including the dividend structure and conversion limitations, are unique to DarioHealth.
• The loan amendment with Avenue Venture Opportunities Fund is a typical debt financing strategy, with the extension of the interest-only period and maturity date contingent on achieving specific financial milestones, similar to other venture debt agreements.
• The company's goal to achieve profitability by the end of 2025 is a common objective for companies in this sector, with many aiming to demonstrate sustainable growth and financial stability.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the conversion of preferred stock and the issuance of additional shares.
• Employees may benefit from the company's improved financial stability and path to profitability.
• Customers may see continued investment in the company's products and services.
• Creditors will benefit from the extended loan maturity date and the company's improved financial position.

Next Steps

• The company will seek stockholder approval for the conversion of preferred stock and the repricing of warrants.
• The company will work towards achieving the financial milestones required for the loan extension.
• The company will continue to execute its strategic plan to achieve operational profitability.

Key Dates

Keywords

private placement, preferred stock, loan amendment, conversion, profitability, cash runway, equity financing, warrants, dividends, DarioHealth